The OCM program is a good start on a path that is as rough as it gets in our healthcare system that needs reform, which can't come from legislation such as Obamacare.
Nash Gabrail, MD
Advertisement
Articles by Nash Gabrail, MD
Advertisement
Latest Updated Articles
The OCM Is Both Good and QuestionablePublished: November 7th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5